启愈生物将公布Q-1802临床Ⅰ期数据
(医药健闻2022年12月21日讯)启愈生物宣布,公司将在当地时间2023年1月19-21日于旧金山会场及线上举行的美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO Gastrointestinal Cancers Symposium)上展示其Q-1802项目的临床Ⅰ期数据。该研究结果摘要将刊登于ASCO GI年会摘要汇集(#382),摘要概览如下:
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs in patients with relapsed or refractory solid tumors
Authors: Yakun Wang1, Jifang Gong1, Yuping Sun2, Jian Zhang3, Yanqiao Zhang4 ,Shuqin ni2, Jie Hou5, Xiaohua Chen5, Yusheng Wang6, Qin Yu7, Xiangdong Qu8, Yejie Du8, Li Wei8, Tao Yu8, Lin Shen1
- Q-1802 is a humanized bispecific antibody
- targets both the tumor -specific antigen CLDN18.2 and the immune checkpoint PD-L1
- Q-1802 has excellent safety, tolerability
- Q-1802 has excellent anti-tumor activity in CLDN18.2 positive GI patients
本文系作者个人观点,转载请注明出处!
赏
支付宝扫码打赏
微信打赏